Drug intelligence / Profile preview

purified omental lipid + polidocanol + palmitoylethanolamide

Development stage
Unknown
Lead developer
Cantabria Labs Difa Cooper
Modality
Small Molecules
Administration
Topical
01

Overview

P.O.L. Calm is a topical dermatological cream developed by Cantabria Labs Difa Cooper. It is a multi-component formulation containing 10% purified omental lipids, polidocanol, and palmitoylethanolamide (PEA). The purified omental lipids serve as emollients to restore the skin barrier and improve skin structure. Polidocanol acts as a local anesthetic and moisturizing agent to alleviate itching. Palmitoylethanolamide is an endogenous fatty acid amide that provides anti-inflammatory and anti-pruritic effects, primarily by acting as an agonist at the peroxisome proliferator-activated receptor alpha (PPAR-alpha). The product is indicated for chronic pruritus and prurigo nodularis, particularly in elderly patients, and has been shown in clinical trials to significantly reduce itch intensity and improve skin barrier function. It is commercially available as a cosmeceutical or dermatological product.

Brand names
P.O.L. Calm
Other names
P.O.L. Calm Cream
02

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on purified omental lipid + polidocanol + palmitoylethanolamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on purified omental lipid + polidocanol + palmitoylethanolamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call